Wednesday, July 21, 2021 1:21:31 PM
oohwee Chuckles a slam dunk. Buyout coming? So how high will we go. My analysis says we go to $1000 plus per share in less than two more years. Yes, there will be offers, big offers, and a big buyout. This is what happens with a miracle drug with multiple remedies for so many different medical indications. They just keep growing as inflammation affects so many vital organs and systems, modes of action, within the body. Take the case of 1990 where Genentech stock went from 1.86 to $98 dollars like an Elon Musk/Bezos rocket.
La Roaches love monoclonal antibodies like when Roche decided they had enough and went for broke and offered $98, think it went for a bit more before deal was done...lol, they
cannot go broke, La Roche is a pack leader and wanted to stay that way. But you get the drift, they were salivating like others are doing right now for CytoDyn. After tomorrows webcast it will sink in for many investors just what an endless diamond mine we have invested in. So a Roche type offer...
In today's dollar, that would be what, say around $700 a share or a bit more when Roche bot a piece of Genentech. They came to realize how big and how fast Genentech was taking over their existing markets. So what to do. But more of course! To the tune of 47 BILLION in 2007.
See, now our leronlimab has a much greater and wider market potential than that deal back 30 years ago. Anyone else remember it?
Of course, Nader cannot say who is wanting a piece of the action.
Our billionaire investor....I know who he is...will want to invest
a bit more real soon so when that day comes for a buyout, the pps will be over a grand per share. How would you like to have ten shares of that?
Think about it. Our day rapidly approaches. When the story is finally written this will be the biggest buyout surpassing the Roach deal. Anyone care to guess the value of the deal. I guess at least 200 billion. https://www.coursehero.com/file/86138060/Roches-Acquisition-of-Genentechdocx/ https://www.cbsnews.com/news/swiss-drug-giant-roche-buys-up-genentech/ 13d knows the value which is why now they want to steal it. Sleeping so well these days I am I am.
La Roaches love monoclonal antibodies like when Roche decided they had enough and went for broke and offered $98, think it went for a bit more before deal was done...lol, they
cannot go broke, La Roche is a pack leader and wanted to stay that way. But you get the drift, they were salivating like others are doing right now for CytoDyn. After tomorrows webcast it will sink in for many investors just what an endless diamond mine we have invested in. So a Roche type offer...
In today's dollar, that would be what, say around $700 a share or a bit more when Roche bot a piece of Genentech. They came to realize how big and how fast Genentech was taking over their existing markets. So what to do. But more of course! To the tune of 47 BILLION in 2007.
See, now our leronlimab has a much greater and wider market potential than that deal back 30 years ago. Anyone else remember it?
Of course, Nader cannot say who is wanting a piece of the action.
Our billionaire investor....I know who he is...will want to invest
a bit more real soon so when that day comes for a buyout, the pps will be over a grand per share. How would you like to have ten shares of that?
Think about it. Our day rapidly approaches. When the story is finally written this will be the biggest buyout surpassing the Roach deal. Anyone care to guess the value of the deal. I guess at least 200 billion. https://www.coursehero.com/file/86138060/Roches-Acquisition-of-Genentechdocx/ https://www.cbsnews.com/news/swiss-drug-giant-roche-buys-up-genentech/ 13d knows the value which is why now they want to steal it. Sleeping so well these days I am I am.
Recent CYDY News
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
